Lorazepam · LORAZEPAM 2 mg/mL · Injection, Solution · Intramuscular; Intravenous · Remedyrepack Inc.
NDC 70518-3766-00 · 10 CARTRIDGE in 1 CARTON / 1 mL in 1 CARTRIDGE · ANDA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “other”.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sterile injectable · price up 94% YoY · OAI inspection at a producing facility (24 months)
For scale: the typical drug’s chance is about 0.1% — this one is 7× that.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hospira, Inc. | LORAZEPAM 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | LORAZEPAM 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Lorazepam — NDC 70518-3766-00," retrieved September 3, 2026, https://drugdashboards.com/drug/70518376600.
Free to cite with attribution — see how the data is put together.